Search results
Showing 2941 to 2955 of 7685 results
NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social...
Our policies and procedures on topics including declarations of interest, gifts and hospitality, complaints, and more.
Guidance Executive
Our role in the Innovative Licensing and Access Pathway (ILAP)
The Innovative Licensing and Access Pathway (ILAP) aims to streamline patient access to safe, financially sustainable and innovative medicines.
We're bringing our guidance together by topic, so that it's all in one place, clearer to understand and easier to access. We expect that this will...
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee. This is called the highly specialised
NICE's research work and partnerships with researchers, funders, charities and policy organisations.
Our board sets out our strategic priorities and policies. The day to day decision-making is the responsibility of our executive team . The...
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
How to use our content for your own purpose. Reuse our guidance, advice, collections and documents.
Find out more about the medical technologies advisory committee members by reading their biographies. Dr Jacob Brown (chair) Biography Jacob
Biographies of the NICE executive team and minutes of their meetings
This indicator covers breast cancer mortality rates (female). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG04
Charging procedure: technology appraisal and highly specialised technologies evaluations
Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly
This indicator covers the proportion of patients with acute myocardial infarction who were discharged on dual antiplatelet therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG95